Literature DB >> 12891193

Mortality trends for 23,505 Medicare patients hospitalized with heart failure in Northeast Ohio, 1991 to 1997.

David W Baker1, Doug Einstadter, Charles Thomas, Randall D Cebul.   

Abstract

BACKGROUND: Clinical trials have identified major therapeutic advances for heart failure (HF), but the degree to which survival has improved among the general population of patients with HF is not known. This study analyzed mortality trends from 1991 to 1997 for 23,505 Medicare patients hospitalized with a first admission for HF at 29 Northeast Ohio hospitals.
METHODS: We linked databases from the Cleveland Health Quality Choice (CHQC) program and Medicare to allow identification of first admissions for HF and death date. We adjusted for changes in admission illness severity using chart data from CHQC (eg, vital signs, do-not-resuscitate status, comorbid conditions, and laboratory results). Logistic regression was used to analyze trends in risk-adjusted mortality.
RESULTS: At baseline (1991), crude inhospital, 30-day and 1-year mortality rates were 6.4%, 8.6% and 36.5%, respectively. Between 1991 and 1997, mean length of stay declined steeply from 9.2 days to 6.6 days (P <.001 for trend). Risk-adjusted inhospital mortality also declined markedly (absolute-decline -3.7%, 95% CI -4.3 to -3.0), a 52.8% relative decrease. However, the decline in 30-day mortality was only -1.4% (95% CI -2.5 to -0.1, P <.05), a 15.3% relative decrease. The 1-year mortality declined -5.3% (95% CI -3.2 to -7.4, P <.001), a 14.6% relative decrease.
CONCLUSIONS: Long-term mortality for patients hospitalized with HF improved from 1991 to 1997, although mortality remains very high. The 30-day mortality declined far less than inhospital mortality, indicating that mortality shortly after discharge increased. This raises concerns that the marked reduction in length of stay is causing adverse consequences.

Entities:  

Mesh:

Year:  2003        PMID: 12891193     DOI: 10.1016/S0002-8703(02)94784-8

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  17 in total

1.  Chronic inotropic therapy in end-stage heart failure.

Authors:  Paul J Hauptman; Peter Mikolajczak; Anil George; Clinton J Mohr; Robert Hoover; Jason Swindle; Mark A Schnitzler
Journal:  Am Heart J       Date:  2006-12       Impact factor: 4.749

2.  Overcoming bias in estimating the volume-outcome relationship.

Authors:  Alexander C Tsai; Mark Votruba; John F P Bridges; Randall D Cebul
Journal:  Health Serv Res       Date:  2006-02       Impact factor: 3.402

3.  Patients with cardiac disease: Changes observed through last decade in out-patient clinics.

Authors:  Alberto Cordero; Vicente Bertomeu-Martínez; Pilar Mazón; Lorenzo Fácila; Juan Cosín; Vicente Bertomeu-González; Moisés Rodriguez; Eva Andrés; Enrique Galve; Iñaki Lekuona; Jose R González-Juanatey
Journal:  World J Cardiol       Date:  2013-08-26

4.  NADPH oxidase inhibition ameliorates cardiac dysfunction in rabbits with heart failure.

Authors:  Yu Liu; He Huang; Wenfang Xia; Yanhong Tang; Haitao Li; Congxin Huang
Journal:  Mol Cell Biochem       Date:  2010-06-22       Impact factor: 3.396

5.  Trends in comorbidity, disability, and polypharmacy in heart failure.

Authors:  Catherine Y Wong; Sarwat I Chaudhry; Mayur M Desai; Harlan M Krumholz
Journal:  Am J Med       Date:  2011-02       Impact factor: 4.965

6.  Is sleep quality related to cognition in individuals with heart failure?

Authors:  Chooza Moon; Cynthia H Phelan; Diane R Lauver; Lisa C Bratzke
Journal:  Heart Lung       Date:  2015-03-18       Impact factor: 2.210

7.  Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006.

Authors:  Héctor Bueno; Joseph S Ross; Yun Wang; Jersey Chen; María T Vidán; Sharon-Lise T Normand; Jeptha P Curtis; Elizabeth E Drye; Judith H Lichtman; Patricia S Keenan; Mikhail Kosiborod; Harlan M Krumholz
Journal:  JAMA       Date:  2010-06-02       Impact factor: 56.272

8.  Eligibility criteria in heart failure randomized controlled trials: a gap between evidence and clinical practice.

Authors:  Giorgio Costantino; Anna Maria Rusconi; Pier Giorgio Duca; Stefano Guzzetti; Ilaria Bossi; Marta Del Medico; Giuseppina Pisano; Mara Bulgheroni; Monica Solbiati; Raffaello Furlan; Nicola Montano
Journal:  Intern Emerg Med       Date:  2008-08-09       Impact factor: 3.397

9.  Short-term mortality and cost associated with cardiac device implantation in patients hospitalized with heart failure.

Authors:  Jason Swindle; Thomas E Burroughs; Mark A Schnitzler; Paul J Hauptman
Journal:  Am Heart J       Date:  2008-06-02       Impact factor: 4.749

Review 10.  Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology.

Authors:  Nathaniel Mark Hawkins; Mark C Petrie; Pardeep S Jhund; George W Chalmers; Francis G Dunn; John J V McMurray
Journal:  Eur J Heart Fail       Date:  2009-02       Impact factor: 15.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.